INNATE PHARMA SA ADR
WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDASiehe auch INNATE PHARMA SA
Frankfurt
18.12.25 | 15:29
1,540 Euro
+2,67 % +0,040
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,400 | 1,520 | 20:07 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12. | Innate Pharma SA: Innate Pharma Releases Its 2026 Financial Calendar | 546 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2026 financial calendar:
March 26, 2026: Publication of 2025 financial... ► Artikel lesen | |
| 28.11. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 28.11. | Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025 | 456 | Business Wire | Regulatory News:
Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General... ► Artikel lesen | |
| 17.11. | Innate Pharma SA: Innate Pharma to Present at Jefferies Global Healthcare Conference | 272 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of... ► Artikel lesen | |
| 13.11. | Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances | 1 | Investing.com | ||
| 13.11. | Innate Pharma reports 9M results | 1 | Seeking Alpha | ||
| 13.11. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln | |||||
| 13.11. | Innate Pharma SA: Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results | 323 | Business Wire | Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndrome IPH4502... ► Artikel lesen | |
| 10.11. | Innate Pharma: Aktie legt nach grünem Licht der FDA für Phase-3-Studie kräftig zu | 13 | Investing.com Deutsch | ||
| 10.11. | Innate Pharma SA: Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL | 387 | Business Wire | The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line... ► Artikel lesen | |
| 05.11. | Innate Pharma SA - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.11. | Innate Pharma SA: Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates | 287 | Business Wire | Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at... ► Artikel lesen | |
| 23.10. | Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating | 2 | Investing.com | ||
| 15.10. | Innate Pharma SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.10. | Innate Pharma SA: Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025 | 371 | Business Wire | The event will provide clinical perspectives and market outlook for lacutamab, Innate's lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase... ► Artikel lesen | |
| 18.09. | Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy | 4 | Investing.com | ||
| 18.09. | Innate Pharma: Leerink Partners stuft Aktie nach strategischem Schwenk herab | 4 | Investing.com Deutsch | ||
| 17.09. | Innate Pharma S.A. GAAP EPS of -€0.25, revenue of €4.9M | 4 | Seeking Alpha | ||
| 17.09. | Innate Pharma: Strategische Neuausrichtung auf Kernprojekte verlängert Liquiditätsreichweite bis Q3 2026 | 2 | Investing.com Deutsch |
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,618 | +2,78 % | BioNTech SE: BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld | BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,522 | +2,01 % | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent... ► Artikel lesen | |
| XOMA ROYALTY | 21,600 | 0,00 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| TME PHARMA | 0,044 | -3,09 % | TME Pharma announces receipt of agreements in principle to extend certain bond agreements | TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage... ► Artikel lesen | |
| CANSINO BIOLOGICS | 4,000 | -3,85 % | CanSino Biologics Inc: Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle | HONG KONG, Aug 20, 2025 - (ACN Newswire) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades... ► Artikel lesen | |
| KARYOPHARM | 5,150 | 0,00 % | Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target | ||
| MEREO BIOPHARMA | 1,705 | +4,28 % | Mereo BioPharma Group plc: Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights | Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027... ► Artikel lesen | |
| ADICET BIO | 0,394 | -4,09 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| KALVISTA PHARMACEUTICALS | 13,000 | +2,36 % | KalVista, Health Catalyst, Bio-Techne Lead After-Hours Gains On Earnings Updates | LONDON (dpa-AFX) - Several healthcare and biotech stocks posted notable gains in Monday's after-hours trading following earnings updates and guidance revisions.KalVista Pharmaceuticals Inc.... ► Artikel lesen | |
| ANNOVIS BIO | 3,125 | +1,13 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| INTEGRA LIFESCIENCES | 11,400 | +2,70 % | INTEGRA LIFESCIENCES HOLDINGS CORP - 8-K, Current Report | ||
| NEUPHORIA THERAPEUTICS | 4,030 | +5,77 % | Neuphoria Therapeutics Inc. - 8-K, Current Report | ||
| RHYTHM PHARMACEUTICALS | 95,50 | 0,00 % | Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome | - - BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising... ► Artikel lesen | |
| RECCE PHARMACEUTICALS | 0,324 | -5,26 % | Recce Pharmaceuticals - Up to A$85m of overseas R&D funding secured | Recce Pharmaceuticals recently reported that the Australian government has agreed to provide it with up to A$85m in future cash rebates over the next three years to reimburse the company's upcoming... ► Artikel lesen |
INNATE PHARMA SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,67 % bei einem Aktienkurs von 1,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INNATE PHARMA SA ADR finden Sie auf Wallstreet Online.